Immunotherapy for high-grade glioma.

Area of Science:

• Neuro-oncology
• Immunotherapy
• Oncology

Background:

• High-grade glioma treatment has seen limited breakthroughs beyond temozolomide.
• Bevacizumab failed to demonstrate survival benefits in major clinical trials (AVaglio, RTOG-0825).
• Novel chemotherapy agents for high-grade glioma are scarce, necessitating alternative therapeutic strategies.

Framework:

• The 4th Quadrennial Meeting of the World Federation of Neuro-Oncology and 18th Annual Meeting of the Society for Neuro-Oncology highlighted immunotherapy's growing importance.
• Presentations focused on advancements in peptide vaccines, dendritic cell-based immunotherapies, gene therapy, and immune checkpoint inhibitors.

Implementation:

• The ReACT study showed safety and efficacy of rindopepimut (peptide vaccine) combined with bevacizumab, with improved survival in patients with higher antibody titers.
• Dendritic cell-based immunotherapy demonstrated safety and the ability to generate sustained immune responses.
• Gene therapy approaches include TOCA 511 for enhanced intratumoral 5-fluorouracil delivery and retroviral coding for temozolomide-resistant lymphocytes.

Implications:

• Immunotherapy represents a promising frontier for managing high-grade glioma, offering potential survival benefits.
• Targeting immune checkpoints (PDL-01, CTLA-4, indoleamine 2,3-dioxygenase) with monoclonal antibodies shows potential therapeutic value.
• These advancements signal a shift towards immune-based strategies in neuro-oncology for a universally fatal disease.